I was trying to help newbies on another forum and posted

New Post Public Reply Private Reply Replies (1) Message Board
petemantx
1,030
I was trying to help newbies on another forum and posted the below but it was deleted as being off-topic. Well done, SS, you A-hole.

For new people checking out IPIX, it has a lot to offer for both traders and investors.

Traders have made a lot of money due to the constant churning in the share price. Forces seem to want to keep the stock price contained but within a range so that money can be made almost daily as the price rises and settles back down at a fast clip. I am not a trader, don't know much about it, but over the years they have been the BIG winners to date.

As for investors, things have been rough for years due to financial concerns (nothing new when talking about a startup biotech with no products yet and drugs taking 10+ years and about $1B to see thru clinical trials) but events have started to move at a dazzling pace in the last 6 months or so and IPIX seems on the verge of finally capitalizing on its megastar drug, Brilacidin. Brilacidin is a synthetic drug, a defensin mimetic, formulated using tens of thousands of hours on super computers so its benefits are many and its drawbacks very small, if even existent.

Brilacidin is now on a pace to possibly cure all, or at least many, of the most severe lower GI tract problems to include Colitis and Crohn's Disease thru the delivery system of a pill. It is on the verge of going to a PhaseIII trial for Oral Mucositis, has already succeeded in a PhaseII antibiotic trial (ABSSSI), and is currently a leading hope to be a treatment or cure for CV19. It has had tests in governmental bio labs that established that it kills the corona virus, works on human kidney tissue in killing CV, and is nearly finished in testing on how it works regarding human lung tissue. Expectations are quite high, extremely high, for this important lung tissue test due to its past trial history. Then it will be ready for use in human CV trials and Brilacidin should become a worldwide household name. The current testing is expected to result in a lot of money (most think in the 10s of millions) granted to IPIX for furher investigation across many fields. Example: The lung testing, when shown successful, should then lead medical authorities to allow Brilacidin to be tested against COPD and Asthma. Its ability to handle CV should also make it a prime candidate as an adjuvant for ALL other virus vaccines, including the flu. To date, it has NEVER met a bacteria in trials it couldn't kill - to include black plague, about 9 different strains of anthrax, etc.

IPIX also has another drug, Kevetrin, that has shown AMAZING results to date in use as a cancer treatment or adjuvant to ALL current cancer treatments. It is the only current drug that has shown it can activate the p53 gene, named the Guardian Angel gene, as it causes the production of the body's natural defensive agents. It needs to be formulated into a pill and currently the pill is about 1/2 way thru tox tests. It is on hold due to lack of funds to proceed further at the current time. But with the expected government grants on the extremely near horizon (most expect grants within a matter of weeks if lung tissue test results are quite good) the Kevetrin pill will be able to be finished and then be put into quite a battery of trials as a stand alone and, more importantly, as an aid to all other current toxic cancer treatments.

The final piece of the puzzle for BOTH Brilacidin and Kevetrin is that besides showing trial results to date of being extremely effective (efficacious), they are also blessed with safety profiles that are so good, having next to NO negative side effects, that they are marvels in the world of medicine today.

Most the boo-hooing you hear on this board is by the traders as they live and die by the daily share price. The true investors you don't hear much from as the trial results speak for themselves. This investment could be the one of a lifetime if things progress as they have been progressing. But then nothing is ever guaranteed so being such a high risk stock be sure that you don't invest what you can't afford to lose.

Innovation Pharmaceuticals Inc (IPIX) Stock Research Links

IPIX Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

UWM Faces Class Action Deadline: Key Insights for Investors

Updated Category News Views 3

The High Stakes Reality for UWM Investors If there's one thing that's certain in this jittery world of investing, it's that losses have a way of waking you up. Right now, anyone tied up with UWM Holdings Corporation (NYSE: UWMC) shares needs to keep their wits about them; we're barreling toward an October 13, 2026 deadline for a class action lawsuit. The clock's ticking...

Continue Reading
First-Time Homeowners: Unseen Pitfalls of Insurance

Updated Category News Views 6

Understanding Homeowners Insurance: Beyond the Basics Most folks diving into homeownership for the first time get caught up in the whirlwind of price tags, loans, and knick-knacks for their new place. Meanwhile, the nitty-gritty of homeowners insurance often gets tossed to the side. But take it from a weary watchdog of financial storms—it’s those details in the policy...

Continue Reading
Trial Disappointment: No Significant Gains in NSCLC

Updated Category News Views 21

Dissecting the Nuances of the EVOKE-03/KEYNOTE-D46 Trial Every once in a while, we come across a trial that rattles cages in the research community. Today, it's the EVOKE-03/KEYNOTE-D46 trial, a collision of hope and hard-knock reality. This Phase 3 trial, which sought to explore the potential combo of sacituzumab govitecan (SG) and pembrolizumab on metastatic non-small...

Continue Reading
Ris-Rez May Set New Standard in Relapsed SCLC

Updated Category News Views 7

The Game-Changing Results Innovation in pharmaceuticals sometimes feels like a waiting game, but when a fresh breakthrough like this rolls in, it lights up the whole landscape. Risvutatug rezetecan, or Ris-Rez for short, has shown promising potential in the fight against relapsed small-cell lung cancer (SCLC) that has progressed after platinum-based therapy. Survival...

Continue Reading
PANDAG G1 Debuts: Revolutionizing Lawn Care Efficiency

Updated Category News Views 6

The Future of Landscaping Unveiled Get this—PANDAG is set to shake things up at GaLaBau 2026 with their futuristic G1 autonomous mower. This isn't just another piece of lawn equipment; it's practically a tech marvel on wheels, weaving together LiDAR, AI Vision, RTK, and 4G tech to make it the ultimate multitasker for the landscaping industry. We're talking obstacle...

Continue Reading
Regeneron Faces Legal Heat: Lead Plaintiff Deadline Looms

Updated Category News Views 6

Regeneron’s Tight Spot: Legal Showdown Well, here we go again—Regeneron Pharmaceuticals (NASDAQ:REGN) is under some serious heat. If you're an investor who faced significant losses with this biotech juggernaut, remember that the clock’s ticking down to the wire. By tomorrow, September 14, 2026, you need to decide if you're going to throw your hat in the ring for...

Continue Reading
Tam-Peli Steps Up in SCLC Battle: Trial Insights

Updated Category News Views 5

Noteworthy Developments in Small-Cell Lung Cancer Treatment Let's dive into a story straight from the world of small-cell lung cancer (SCLC) that doesn't take any prisoners. The antidote making waves is tambotatug pelitecan, or Tam-Peli for short, showcasing its might in the unrelenting fight against relapsed SCLC. The phase III TAISHAN-302 trial puts Tam-Peli...

Continue Reading
GORGIE Unleashes Berry Burst: Target's New Drink Star

Updated Category News Views 6

GORGIE Targets Taste Buds with Berry Burst Ever feel like you're missing out on that energy drink everyone seems to be raving about? Well, GORGIE's out there making some noise again, and this time it's got a new punchy player in the game: Berry Burst. It's not just another drink; it's shaking things up in the energy aisle with its exclusive launch at Target. Modern style...

Continue Reading
MRI Surveillance Gains Ground in Lung Cancer Care

Updated Category News Views 7

Shifting the Standard: MRI's Rise in SCLC Treatment Here's a twist that baffles the traditionalists—ditch the prophylactic cranial irradiation (PCI) and catch clearer days with MRI surveillance for small-cell lung cancer (SCLC). The latest international phase III MAVERICK trial might just redraw the lines on what's considered standard care in this relentless disease....

Continue Reading
PwC US and India Unite for Global Consultancy Powerhouse

Updated Category News Views 7

Rearranging the Consultancy Chessboard Piling onto the game of consultancy realignments, PwC just made a move reminiscent of playing strategy poker. They're tossing together PwC US and PwC India's advisory capabilities for a new joint venture. It’s like pushing two puzzle pieces to make a single colorful picture that stretches from the U.S. all the way to the...

Continue Reading

Top 5 Most Recently Viewed Articles

Cytokinetics Faces Class Action: What You Need to Know

Updated Category News Views 175

Understanding the Class Action Lawsuit Against Cytokinetics Cytokinetics, Incorporated is currently facing a significant class action lawsuit initiated by shareholders. This legal challenge brings to light serious allegations against the Company regarding their disclosures and expectations for FDA approval of a key drug. Details of the Allegations The lawsuit asserts that...

Continue Reading
Discover the Embodied Luxury of the Champagne Specialist Course

Updated Category News Views 207

Verona Hosts the Esteemed Champagne Specialist Course The Italian Wine Academy is excited to announce a remarkable opportunity for wine enthusiasts and professionals. In Verona, for the very first time, the Academy will conduct the prestigious Comité Champagne 'Champagne Specialist' course. This unique program will be available in both English and Italian, providing an...

Continue Reading
MiniLuxe Achieves Strong Q1 2025 Growth with Strategic Focus

Updated Category News Views 378

MiniLuxe Reports Strong Financial Performance for Q1 2025 Reported figures all in U.S. Dollars MiniLuxe Holding Corp. (TSXV: MNLX) has announced exciting financial results for its first quarter of the year. This period showcased a significant 9% growth in revenue, reaching an impressive $6.1 million. Coupled with a gross profit of $2.5 million, reflective of a 12%...

Continue Reading
Transforming Shopify: AI Product Discovery for Enterprises

Updated Category News Views 141

Fredhopper's New App for Shopify Fredhopper Introduces Cutting-Edge Product Discovery Solutions The ecommerce landscape is evolving rapidly, and innovation is at the forefront. Fredhopper has launched its Product Discovery App for Shopify, bringing advanced AI-powered product search and personalized recommendations directly into the hands of enterprise merchants. This...

Continue Reading
Quantum Computing Inc. Faces Class Action Lawsuit for Shareholders

Updated Category News Views 162

Understanding the Recent Class Action Against Quantum Computing Inc. In a significant turn of events, Quantum Computing Inc. has come under legal pressure as a class action lawsuit has been filed on behalf of its shareholders. The lawsuit comes in response to allegations of misleading information that may have adversely affected investors' financial interests. Class...

Continue Reading